Clinical trials
Tumor clinical trials
Below are recruiting tumor clinical trials, each written for real people, not researchers. We’re tracking 3,403 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07181681RecruitingPhase 1
Study of BG-C0902 for advanced solid tumors
This trial tests a new drug, BG-C0902, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapies. The goal is to see if it is safe and effective.
Houston, TexasAges 18 years+ - NCT07159126RecruitingPhase 1
Study of DS3610a for advanced solid tumors
This trial tests a new drug called DS3610a for people with advanced solid tumors that have stopped responding to other treatments. You may be able to join if you have tried standard therapies and are willing to provide a tumor sample.
ChūōkuAges 18 years+ - NCT06474455RecruitingPhase 1/Phase 2
Study of SHR-9839 with other treatments for advanced solid tumors
This trial tests a new drug called SHR-9839 combined with other cancer treatments for people with advanced solid tumors, including a certain type of lung cancer. The goal is to see if the combination is safe and effective against the cancer.
Zhengzhou, HenanAges 18–75 - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07399769RecruitingPhase 1/Phase 2
MSLN CAR-T therapy for advanced solid tumors
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
Shenzhen, Other (Non U.s.)Ages 18–75 - NCT06488950RecruitingEarly Phase 1
TIL therapy for advanced solid tumors
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
ShanghaiAges 18–75 - NCT05705687Recruiting
Testing a treatment plan for higher-risk testicular cancer
This trial checks whether a specific treatment approach works better for men with higher-risk non-seminomatous germ-cell tumors that have spread. Doctors will use tumor marker changes and where the cancer started (often the chest area) to help guide treatment choices.
VillejuifAges 16 years+ - NCT07349160RecruitingEarly Phase 1
Metabolically armed TIL therapy for advanced solid tumors
This trial tests a new cell therapy called Meta10-TIL, where immune cells from your tumor are modified and given back to you to help fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
BeijingAges 19–70 - NCT06598371RecruitingPhase 1/Phase 2
Study of engineered immune cells for advanced solid tumors
This trial tests a new treatment made from your own immune cells (called tumor-infiltrating lymphocytes) that are genetically modified to fight cancer better. It is for people with certain advanced solid tumors that have not responded well to other treatments.
Houston, TexasAges 18 years+ - NCT06960395RecruitingPhase 1
Study of VIR-5525 alone or with pembrolizumab for advanced solid tumors
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Scottsdale, ArizonaAges 18 years+ - NCT05661201RecruitingPhase 1
Testing a KRAS drug and doxorubicin for certain solid tumors
This Phase 1 study tests a drug called NEROFE together with doxorubicin in people whose tumors have a specific KRAS mutation and show ST2 in tumor tissue. It’s meant to find the safest dose and whether the treatment can shrink or control these advanced cancers.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06047977RecruitingPhase 1
Immune cell therapy for high-risk solid tumors in children and young adults
This trial uses a patient's own tumor-fighting immune cells (TILs) to treat high-risk solid tumors outside the brain in children and young adults. It has two parts: first, a tumor sample is collected during surgery, and then the immune cells are grown in a lab and given back to the patient to attack the cancer.
St. Petersburg, FloridaAges 1–21 - NCT05868174RecruitingPhase 1
Testing a targeted radiation drug plus a DNA repair blocker
This early-phase trial tests whether combining a targeted radiation medicine (177Lu-TLX250) with a DNA repair–blocking drug (peposertib) can shrink advanced solid tumors. It is designed for tumors that strongly show a marker called CAIX, which helps the radiation home in and may make treatment more effective.
North Ryde, New South WalesAges 18 years+ - NCT06279130RecruitingPhase 2/Phase 3
New immunotherapy before surgery for multiple cancer types
This trial tests new immunotherapy combinations given before surgery for cancers that have certain genetic features (dMMR or pMMR). It aims to see if these drugs can shrink tumors and improve outcomes for patients with various cancer types, including those for which standard neoadjuvant therapy is not an option.
Amsterdam, North HollandAges 18 years+ - NCT05981703RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new drug (BGB-26808) alone or with another drug (tislelizumab) for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the combination can help shrink tumors or slow their growth.
Duarte, CaliforniaAges 18 years+ - NCT05811975RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors
This early-phase study tests a personalized treatment made from your own immune cells to attack solid tumors that have not responded to standard care. If you qualify, the team will collect blood cells, prepare the therapy, and give it back to you with close monitoring for safety and early signs of benefit.
Nanning, GuangxiAges 18–70 - NCT07229586RecruitingPhase 1/Phase 2
Study of SHR-7367 with other cancer drugs for solid tumors
This trial tests a new drug called SHR-7367 combined with other cancer medicines for people with solid tumors. It aims to see if the combination is safe and effective.
Tianjin, Tianjin MunicipalityAges 18–75 - NCT06150365RecruitingEarly Phase 1
Personalized T-cell therapy for advanced solid tumors (KSX01-TCRT)
This study tests a personalized treatment made from your own immune cells (T cells) that are re-engineered to recognize and attack your specific tumor. It is for people with advanced solid tumors that have not responded to other treatments. If you qualify, you will have a blood draw and a tumor sample collected to create your own custom T cell therapy.
BeijingAges 18–70 - NCT05831033RecruitingEarly Phase 1
Your own immune T-cells to treat advanced solid tumors
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05907980RecruitingPhase 1
ROSE12 alone and with other drugs for advanced solid tumors
This trial tests a new drug called ROSE12, given alone or with other cancer treatments, for people with advanced solid tumors that have not responded to standard therapies. The study aims to see if ROSE12 is safe and effective.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06638034RecruitingEarly Phase 1
New imaging and radiation therapy for metastatic tumors
This trial tests a new type of imaging scan and treatment for cancers that have spread. You would first have two special scans, then you may receive a targeted radiation therapy (177Lu-FAPI-RGD) to see if it can help shrink tumors.
Beijing, Beijing MunicipalityAges 18–90 - NCT07368803RecruitingPhase 1/Phase 2
Personalized mRNA vaccine for bile duct cancer after surgery
This trial tests a personalized mRNA vaccine (iNeo-Vac-R01) made from your tumor's unique markers to help prevent cancer from coming back after surgery for bile duct or other digestive cancers. It may be an option if standard treatments have stopped working or caused side effects.
Hangzhou, ZhejiangAges 18–75 - NCT02333110Recruiting
Grid radiation therapy for advanced, painful tumors
This trial tests a way of giving palliative radiation using a “grid” to treat advanced tumors that are large, resistant to standard radiation, or already needed more than one palliative radiation session. It may help better control symptoms when a cure is not the goal.
Montreal, QuebecAges 18 years+ - NCT07140393RecruitingPhase 1/Phase 2
Combination therapy for advanced solid tumors
This study tests a new drug called HRS-4508 combined with other cancer treatments for people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to see if the combination is safe and effective.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for tumor?
- Yes. Clin2 currently lists 3,403 recruiting tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.